Treatment of Advanced Thymic Carcinoid: Typical or Slowly Progressing, SRI-Positive
This protocol covers the management of advanced or metastatic thymic carcinoid in the specific setting of typical carcinoid or slowly radiologically progressing disease that is positive on somatostatin receptor imaging, without atypical or significantly progressive features.
Clinical scenario
- Advanced / metastatic thymic carcinoid
- Typical carcinoid, or slowly radiologically progressing
- Somatostatin receptor imaging (SRI)-positive
- No atypical or significantly progressive features
Treatment approach (partial overview)
When chemotherapy is indicated in this setting, dacarbazine/temozolomide-based chemotherapy represents the first-line approach. Additional chemotherapy lines are defined within the full protocol for patients who require further treatment.
The complete regimen, sequencing criteria, and full algorithm are available in the structured protocol below.
References
DOI: 10.1016/j.annonc.2021.01.003
- SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
- Dacarbazine/temozolomide-based ChT as first line, and platinum-based ChT as second line, are recommended in advanced LC patients refractory or intolerant to everolimus therapy [IV, C]
- Among platinum-based agents, oxaliplatin-based ChT is recommended by the majority of the panel [IV, C].
View source ↗